FTC (Federal Trade Commission) probes DaVita/Gambro Healthcare deal further
This article was originally published in Clinica
The US Federal Trade Commission (FTC) has requested additional information from DaVita and Gambro regarding the former's planned $3.05bn acquisition of the latter's Gambro Healthcare US dialysis services business. A spokesperson for Stockholm, Sweden-based Gambro told Clinica: "We believe that any antitrust issues can be overcome." She added that the deal was a very good one for both parties.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.